Skills Alliance’s Post

🥐 De bonnes nouvelles pour la #France ce matin! 🥐 💊 Leading pharmaceutical companies like Sanofi, GSK, Pfizer, and AbbVie are making substantial investments in R&D, clinical research, and drug production in northern France. 🔬 These initiatives are expected to generate over 800 new #jobs between 2024 and 2026 and produce top-tier #pharmaceuticals. 💲 Sanofi's commitment alone, with over 1 billion euros earmarked for expanding manufacturing capacity and constructing a new facility in Vitry-sur-Seine, highlights the region's emergence as a hub for innovation in healthcare. 📈 The investments not only foster economic growth but also underscore the companies' dedication to advancing healthcare solutions and creating opportunities for skilled professionals. https://lnkd.in/d6SWTUwa

Pfizer and others pledge over €1 Billion to expand clinical research and trials in France Multiple Biopharma giants have announced substantial investments in France under the country's "Choose France" initiative. Pfizer pledged €500 million over five years to focus on clinical research and trials, particularly for sickle cell disease and multiple myeloma. Industry leaders including AstraZeneca, Novartis, and Sanofi also announced plans for strategic investments to help boost the country's pharmaceutical production capabilities. AstraZeneca's €365 million pledge will go to enhancing their Dunkirk manufacturing facilities, and other biopharma companies, including AbbVie, GSK, Chiesi Group, and Kenvue, also announced sizable investments. At OxyDial, our mission is to help streamline the research and development of new treatments for inherited blood disorders. We're thrilled to see strategic investments that expand the possibilities for research and trials that improve the quality of life for affected patients worldwide. Read more: https://lnkd.in/eypai_xd #ClinicalTrials #RareDiseases #PatientCare #Pfizer #AstraZeneca #Novartis #Sanofi #AbbVie #GSK #OxyDial #HealthcareInnovation

Biopharma investment is blooming in France despite the push of many companies to streamline operations. Biopharma companies leading the way during "Choose France," a summit to boost foreign investment in the country, are Sanofi, Pfizer and AstraZeneca. The initiative was created to boost foreign investment by showcasing the advantages multinational companies can realize in France.  #France #Investment #capital #biopharma #biomanufacturing https://lnkd.in/eh5Y-8ax.

🌟 Big news for the pharmaceutical industry! Sanofi, Pfizer, and AstraZeneca pledge nearly $2.16 billion in total investments in #France, highlighting their commitment to innovation and growth in the country. This significant investment will not only drive advancements in healthcare but also boost the local economy and create job opportunities. Exciting times ahead for the French biopharma sector! 💼💡 #PharmaIndustry #Investment #Innovation #France Reuters Article from Tristan Cesar Mañalac for BioSpace :

Sanofi, Pfizer, and AstraZeneca are investing a combined €1.87 billion to enhance their operations in France, a move driven by the “Choose France” initiative to attract foreign investment and bolster the country’s pharmaceutical capabilities. This move raises important questions for the UK’s life sciences sector: What strategies will the UK adopt to attract similar investments? How can we focus on improving the regulatory environment, increasing R&D incentives, or investing in innovative technologies to remain competitive with the rest of Europe? Should the UK government be doing more to support the life sciences industry? #lifesciences #biotech #pharma #UKinnovation https://lnkd.in/eZ4S2dJB

France: The Pharma-Place-to-Be in 2024! 🌟 Exciting developments are happening in the pharmaceutical world, and France is at the forefront of it all. According to Fierce Pharma, major investments are pouring into R&D and manufacturing in the EU, with France taking a leading role. Sanofi is investing $1.1B in treatments for COPD, Asthma, MS, and T1D, along with over $100M to boost Dupixent and an additional $10M+ for TZIELD. AstraZeneca is committing nearly $400M to its initiatives. Pfizer plans to spend over $500M on R&D in the next five years. These are just a few examples, with other significant investments coming from AbbVie, Novartis, Kenvue, and Chiesi Group. What's particularly intriguing is the dynamic shift we're witnessing: while the EU, particularly France, is becoming a hub for R&D and manufacturing, US companies are focusing on direct-to-patient initiatives. This includes direct contracts with pharmacies, diagnostics, and telehealth providers. 🔄 Produce and Innovate in Europe, Sell in the US 🔄 The future of pharma looks promising with this transatlantic synergy! For more insights, check out the full article from Fierce Pharma: https://lnkd.in/dQ9rB6ks

𝐌𝐞𝐢𝐫𝐚𝐆𝐓𝐱 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐀𝐬𝐬𝐞𝐭 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 𝐈𝐧𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐢𝐭𝐬 𝐀𝐀𝐕-𝐑𝐏𝐆𝐑 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐮𝐩 𝐭𝐨 $𝟒𝟏𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 MeiraGTx Holdings plc (Nasdaq: MGTX) MeiraGTx has finalized an asset purchase agreement with Janssen Pharmaceuticals, Inc. (J&J) The Janssen Pharmaceutical Companies of Johnson & Johnson, a Johnson & Johnson company, for the remaining interests in bota-vec, targeting XLRP. This collaboration includes a commercial supply agreement and a technology transfer agreement for bota-vec manufacturing. Alexandria Forbes, Ph.D., CEO of MeiraGTx, shared, “We are pleased to announce these agreements, providing us with significant near-term cash, potential approval milestones, and revenue from bota-vec commercial manufacture. The $130 million upfront payment, combined with our recent $30 million investment from Sanofi, enhances our financial position until mid-2026." Dr. Forbes added, "This positions us well to focus on our late-stage clinical programs in Xerostomia and Parkinson’s disease, and our end-to-end manufacturing capabilities. We're also advancing our Riboswitch gene regulation platform, prioritizing targets in metabolic disease, immunology, and oncology." Agreements include: J&J acquiring remaining rights for bota-vec development, manufacturing, and commercialization. MeiraGTx receiving $130 million upfront and near-term milestone payments. An additional $285 million possible upon the first commercial sales of bota-vec in the U.S. and EU and for manufacturing technology transfer. Commercial supply agreement with J&J for bota-vec manufacturing. #collaboration #healthcare #investment #pharmaceutical #parkinsonsdisease #treatment #therapeutics

Pharmaceutical company AstraZeneca has set an ambitious target to increase its total revenue to $80 billion by 2030, a 75% rise from $45.8 billion in 2023. This growth will be driven by a robust pipeline focusing on oncology, biopharmaceuticals, and rare diseases, with plans to release 20 new medicines over the next six years. AstraZeneca's Chief Financial Officer, Aradhana Sarin, expressed confidence in achieving this goal, highlighting the potential for many of these new drugs to generate $5 billion annually at their peak. The announcement has already positively impacted AstraZeneca's stock, with shares rising 0.66% following the news. AstraZeneca's strategic focus includes developing treatments for a wide range of cancers and creating alternatives to traditional therapies like chemotherapy and radiation. Additionally, AstraZeneca is investing in advanced manufacturing capabilities, including a new antibody-drug conjugate facility in Singapore, to support the production of these innovative therapies. This investment underscores the company's commitment to leveraging cutting-edge technology to transform cancer treatment. In the post-COVID era, AstraZeneca is shifting its focus back to its core areas of expertise, such as oncology and cardiovascular health, while also exploring new opportunities in diabetes and metabolic diseases. The company is entering the competitive weight management market, aiming to develop drugs that address both weight loss and related comorbidities. This strategic pivot follows the decision to withdraw its COVID-19 vaccine, Vaxzevria, due to declining demand and the availability of newer vaccines. AstraZeneca's continued investment in innovation and strategic acquisitions, such as Fusion Pharmaceuticals, positions it well for sustained growth and leadership in the pharmaceutical industry. #ASpireLifeSciences #astrazeneca #drugdiscovery #pharma #pharmaceuticals https://lnkd.in/eiV6SiZ6

🚀 Exciting news in drug innovation! Sanofi acquires Inhibrx, Inc. for $2.2 Billion! 💊💡 🌐 Strategic Move: Breaking ground in drug development, Sanofi is set to acquire California-based biotech, Inhibrx, in a deal valued at up to $2.2 billion. This strategic move aims to fortify Sanofi's pipeline of inflammation-targeting drugs. 🌍💉 🎯 Fighting AATD: At the core of this collaboration is Inhibrx's INBRX-101, a revolutionary therapy combating Alpha-1 Antitrypsin Deficiency (AATD). With Phase 1 testing completed, the drug is now in Phase 2 trials, offering hope for patients with this debilitating disease affecting the lungs and liver. 💪🔬 🔄 A New Inhibrx Chapter: As part of the deal, Inhibrx's array of drug candidates, featuring cancer-targeting immunotherapies, will form a standalone company, preserving the Inhibrx brand. Mark Lappe, Inhibrx's visionary founder and CEO, will continue to lead this new era of innovation. 🚀👨💼 💼 Strategic Outlook: This acquisition not only underscores Sanofi's commitment to expanding its therapeutic portfolio but also positions the newly formed Inhibrx company to drive advancements in immunotherapies and other cutting-edge drug candidates. 💊💼 🌟 Leadership Continuity: With Mark Lappe at the helm, there's a seamless transition ensuring expertise and innovation in steering Inhibrx toward new milestones. Sanofi's investment aligns with the pursuit of pioneering solutions in the healthcare landscape. 👥🚢 👩⚕️🤝 #SanofiInnovation #DrugDiscovery #HealthcareAdvancement #InhibrxAcquisition 🌐💊